Subject to the passage of legislation, effective 1 November 2025 the following amended pathology items will be listed on the Medicare Benefits Schedule (MBS):

• Introduce a new MBS item for faecal calprotectin (FC) testing for symptomatic patients with Inflammatory Bowel Disease (IBD).
• Introduce a new MBS item for dihydropyrimidine dehydrogenase (DPYD) genotyping to predict or diagnose fluoropyrimidine (FP)-induced toxicity.
• Amend MBS items (73374, 73375, and 73376) for somatic gene testing of sarcomas to allow clinicians to choose which genes to test and to allow more frequent testing.
• Introduce a new MBS item for Fibroblast growth factor 23 (FGF-23) testing for patients with a high pre-test probability of X-linked hypophosphatemia (XLH) to determine eligibility for burosumab on the Pharmaceutical Benefits Scheme (PBS).
• Amend the Health Insurance (Pathology Services Table) Regulations 2020 for clinically indicated gross and histologic examination of placentas in perinatal deaths from current level 4 complexity tissue examinations to level 5 and level 6 complexity tissue examinations.
• Amend non-small cell lung cancer (NSCLC) MBS items to restructure and refer to ‘relevant treatments’ under the Pharmaceutical Benefits Scheme (PBS) in a consistent manner.
• Enable midwives to request MBS items 73420 and 73421 for Rhesus D (Rh D) non-invasive prenatal testing (NIPT) of eligible, pregnant patients.

Further information will be provided below as it becomes available:

Factsheet	PDF and Word versions
New MBS item for faecal calprotectin testing (Last updated: 9 July 2025)	Word Version - New Medicare Benefits Schedule item for faecal calprotectin testing.docx PDF Version - New Medicare Benefits Schedule item for faecal calprotectin testing.pdf